A report from MedPage Today last week suggests there is no role for denosumab (Xgeva or Prolia) in early stage, high risk breast cancer that is bone mets free. Read the article here.
There are many similarities between breast and prostate cancer in their respective disease patterns. Our PCa groups often discuss the timing of bone strengthener use. A quick review of the literature reveals one meta-study that supports the use of denosumab.; however it does not analyse the results by disease stage of those studied.
This is of personal interest to the Author’s experience. I was placed on bone support treatment at the outset of 28 months hormone deprivation therapy because my bone density was borderline osteoporitic, albeit no observed bone mets – and it helped me over the course of my treatment. Since baseline bone density at start of treatment is a relevant factor, why was that not factored into the equation?